🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "major milestone" in the fight against drug-resistant strains of the infection, according to health experts.

A Worldwide Health Concern

The sexually transmitted infection are increasing globally, with figures suggesting in excess of 82 million new cases annually. Notably increased rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have reached a historical peak, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an important and timely advancement in the reality of growing infection rates, increasing antimicrobial resistance and the highly restricted therapeutic options presently on offer.”

Public health authorities are particularly alarmed about the surge in antibiotic-resistant strains. The World Health Organization has classified it as a "priority pathogen". A tracking program showed that the effectiveness of standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Drugs Secure Authorization

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the US Food and Drug Administration in recent days for treating gonorrhoea. This disease can lead to significant complications, including infertility. Scientists anticipate that focused deployment of this new drug will help slow the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This medication, which is also used to treat UTIs, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin emerged from a unique collaborative effort for medication research. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to develop it.

“This approval signifies a major breakthrough in the management of superbug gonorrhoea, which previously has been outpacing medical innovation.”

Research Study Results and Worldwide Availability

According to findings released by a major medical journal, the new drug eradicated more than 90% of genital gonorrhoea infections. This puts it on an comparable level with the current standard treatment, which uses an injection and a pill. The trial involved over 900 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the authority to make available and distribute the drug in many regions with limited resources.

Doctors directly involved have expressed positive views. The availability of a single-dose, oral treatment like this is described as a "game-changer" for gonorrhoea control. This is deemed essential to lessen the impact of the infection for people and to halt the transmission of extremely resistant gonorrhoea around the world.